Second-Guessing FDA? Sage Zulresso Denied Add-On Status In Medicare
Executive Summary
Medicare’s doubts about trial design for Sage’s postpartum depression therapy suggests even ‘breakthrough’-designated products can struggle with the ‘substantial clinical improvement’ standard for NTAP status. Denial of enhanced payment for Zulresso ends a long winning streak by innovators.
You may also be interested in...
Medicare Part B Shift To Discourage Prescribing Of Costly New 340 Drugs Weighed By MedPAC
Linking clinical superiority to payments is another recommendations on Medicare reimbursement for separately payable drugs in the hospital outpatient prospective payment system under consideration by the Medicare Payment Advisory Commission.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.